nt-175
nt-175: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: ASTRAZENECA PLC (AZN)
Development Pipeline (1)
| Company | Phase |
|---|---|
| ASTRAZENECA PLC (AZN) | Phase 1 |
Clinical Trials (1)
An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation
Frequently asked questions
Who is developing nt-175?
nt-175 is being developed by ASTRAZENECA PLC.
How many clinical trials involve nt-175?
BioSniper tracks 1 clinical trial involving nt-175.
Analyze ASTRAZENECA PLC & nt-175 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company